MyFinsight
Home
Blog
About
Proceeds from maturities
and sales of...
$217,993K
(-57.16%↓ Y/Y)
Net proceeds from
stock option...
$3,149K
(87.00%↑ Y/Y)
Net cash provided by
investing activities
$40,210K
(-79.01%↓ Y/Y)
Net cash provided by
financing activities
$3,149K
(87.00%↑ Y/Y)
Canceled cashflow
$177,783K
Net change in cash
and cash...
-$13,953K
(-401.75%↓ Y/Y)
Canceled cashflow
$43,359K
Expense associated with
license agreement
$25,000K
(150.00%↑ Y/Y)
Stock-based compensation
expense
$15,941K
(-38.81%↓ Y/Y)
Accrued expenses and
other current...
$8,354K
(172.19%↑ Y/Y)
Inventory
-$4,935K
(-252.69%↓ Y/Y)
Non-cash operating lease
expense
$3,321K
(-45.50%↓ Y/Y)
Accounts payable
$3,080K
(184.13%↑ Y/Y)
Depreciation and
amortization
$1,350K
(-46.79%↓ Y/Y)
Other non-current
liabilities
$940K
(220.67%↑ Y/Y)
Purchases of marketable
securities
$151,571K
(-50.42%↓ Y/Y)
Payments associated with
license agreement
$25,000K
(150.00%↑ Y/Y)
Purchases of property and
equipment
$1,212K
(-26.14%↓ Y/Y)
Net cash used in
operating activities
-$57,312K
(69.61%↑ Y/Y)
Canceled cashflow
$62,921K
Net loss
-$100,703K
(49.98%↑ Y/Y)
Prepaid expenses and
other current and...
$4,888K
(30.49%↑ Y/Y)
Operating lease
liabilities
-$4,574K
(44.41%↑ Y/Y)
Contract assets
$4,104K
Accounts receivable, net
$3,980K
(353.82%↑ Y/Y)
Net accretion of
discount on marketable...
$1,127K
(-70.09%↓ Y/Y)
Realized gain on
investments
$67K
(3250.00%↑ Y/Y)
Back
Back
Cash Flow
AGIOS PHARMACEUTICALS, INC. (AGIO)
AGIOS PHARMACEUTICALS, INC. (AGIO)
source: myfinsight.com